Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Liabilities and Shareholders Equity: 2016-2025

Historic Liabilities and Shareholders Equity for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $368.0 million.

  • Rocket Pharmaceuticals' Liabilities and Shareholders Equity fell 6.52% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 6.20%. This contributed to the annual value of $527.7 million for FY2024, which is 6.82% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $368.0 million for Q3 2025, which was down 12.58% from $421.0 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Liabilities and Shareholders Equity peaked at $598.8 million during Q3 2023, and registered a low of $368.0 million during Q3 2025.
  • Over the past 3 years, Rocket Pharmaceuticals' median Liabilities and Shareholders Equity value was $471.1 million (recorded in 2025), while the average stood at $479.0 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Liabilities and Shareholders Equity surged by 58.05% in 2021 and then crashed by 34.25% in 2024.
  • Rocket Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $497.0 million in 2021, then grew by 11.02% to $551.8 million in 2022, then rose by 2.63% to $566.3 million in 2023, then decreased by 6.82% to $527.7 million in 2024, then dropped by 6.52% to $368.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $368.0 million in Q3 2025, compared to $421.0 million in Q2 2025 and $471.1 million in Q1 2025.